Henry Schein Inc
NASDAQ:HSIC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62.03
81.91
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Henry Schein Inc
In the evolving landscape of healthcare distribution, Henry Schein Inc. has carved out a robust niche, establishing itself as a pivotal player in delivering essential products and services. Founded in 1932, the company initially responded to the growing need for medical supplies with a simple commitment to customer service and innovation. Today, the company profiles as the world’s largest provider of healthcare products and services to office-based dental and medical practitioners, alongside its veterinary arm. It services a global footprint, channeling its efforts into dental, medical, and animal health sectors. The company's sprawling network deploys a vast array of products—from consumables to equipment—to a multitude of healthcare professionals, accentuating its integral role in the clinical toolkit.
Henry Schein's revenue engine thrives on a meticulously crafted business model that combines the breadth of a comprehensive catalog with targeted value-added services. Its diverse product offerings span dental implants, vaccines, pharmaceuticals, and surgical supplies, delivered through direct sales and sophisticated logistical frameworks. Moreover, Henry Schein supplements its product lines with a suite of services, including practice management solutions and e-commerce platforms, that streamline operations for practitioners and enhance client loyalty. Strategic partnerships and acquisitions show the company's commitment to innovation, driving efficiencies and expanding its reach. This continuous adaptation keeps Henry Schein at the forefront of healthcare trends, ensuring steady streams of income flowing from both longstanding relationships and new market opportunities.
In the evolving landscape of healthcare distribution, Henry Schein Inc. has carved out a robust niche, establishing itself as a pivotal player in delivering essential products and services. Founded in 1932, the company initially responded to the growing need for medical supplies with a simple commitment to customer service and innovation. Today, the company profiles as the world’s largest provider of healthcare products and services to office-based dental and medical practitioners, alongside its veterinary arm. It services a global footprint, channeling its efforts into dental, medical, and animal health sectors. The company's sprawling network deploys a vast array of products—from consumables to equipment—to a multitude of healthcare professionals, accentuating its integral role in the clinical toolkit.
Henry Schein's revenue engine thrives on a meticulously crafted business model that combines the breadth of a comprehensive catalog with targeted value-added services. Its diverse product offerings span dental implants, vaccines, pharmaceuticals, and surgical supplies, delivered through direct sales and sophisticated logistical frameworks. Moreover, Henry Schein supplements its product lines with a suite of services, including practice management solutions and e-commerce platforms, that streamline operations for practitioners and enhance client loyalty. Strategic partnerships and acquisitions show the company's commitment to innovation, driving efficiencies and expanding its reach. This continuous adaptation keeps Henry Schein at the forefront of healthcare trends, ensuring steady streams of income flowing from both longstanding relationships and new market opportunities.
Sales Growth: Henry Schein reported global sales of $3.3 billion for Q3 2025, up 5.2% from last year, with growth accelerating across all segments.
Margin Dynamics: Operating margin was 4.88%, down 6 bps year-over-year, but non-GAAP operating margin improved 19 bps to 7.83%, helped by lower operating expenses.
EPS and Profit: Q3 net income was $101 million ($0.84 per share), up from $99 million ($0.78 per share) last year. Non-GAAP EPS was $1.38, higher than the prior year’s $1.22.
Value Creation Initiatives: Management expects over $200 million in operating income improvements over the next few years from operational streamlining and efficiency projects.
Raised Guidance: 2025 non-GAAP EPS guidance was raised to $4.88–$4.96 and sales growth to 3–4% over 2024, reflecting Q3 strength and a remeasurement gain.
Buybacks: Share repurchases totaled $229 million in Q3, and the Board approved a $750 million increase to the buyback program.
KKR Partnership: KKR was given approval to increase its stake to 19.9%, deepening the strategic partnership and its input on operational initiatives.
CEO Transition: Stanley Bergman confirmed retirement as CEO at year-end, with a formal search for his successor ongoing and transition plans in place.